ISO 14155-2020医疗器械临床实验管理规范
VIP免费
Clinical investigation of medical
devices for human subjects — Good
clinical practice
Investigation clinique des dispositifs médicaux pour sujets humains —
Bonne pratique clinique
© ISO 2020
INTERNATIONAL
STANDARD
ISO
14155
Third edition
2020-07
Reference number
ISO 14155:2020(E)
Copyright International Organization for Standardization
Provided by IHS Markit under license with Standards Council of Canada
Not for Resale, 08/01/2020 07:24:26 MDT
No reproduction or networking permitted without license from IHS
--`,``,,`,``,`,,`,,,,,,,,,````-`-`,,`,,`,`,,`---
ISO 14155:2020(E)
ii © ISO 2020 – All rights reserved
COPYRIGHT PROTECTED DOCUMENT
© ISO 2020
Website: www.iso.org
Copyright International Organization for Standardization
Provided by IHS Markit under license with Standards Council of Canada
Not for Resale, 08/01/2020 07:24:26 MDT
No reproduction or networking permitted without license from IHS
--`,``,,`,``,`,,`,,,,,,,,,````-`-`,,`,,`,`,,`---
ISO 14155:2020(E)
Foreword ..........................................................................................................................................................................................................................................v
1 Scope ................................................................................................................................................................................................................................. 1
2 Normative references ...................................................................................................................................................................................... 1
..................................................................................................................................................................................... 1
4 Summary of good clinical practice (GCP) principles ....................................................................................................... 9
5 Ethical considerations .................................................................................................................................................................................10
........................................................................................................................................................................................................ 10
....................................................................................................................................10
.................................................................................................................... 10
.............................................................................................................. 11
5.5 Responsibilities ...................................................................................................................................................................................11
...................................................................................................11
................................................................................................................................................................................... 11
................................................................................................................................................. 11
................................................................................................... 12
................................................................................................... 12
..................................................................... 12
................................................................................................................................................................. 12
...............................................................................................................................................................................13
................................................................................................................................................................................... 13
..................................................................................................... 13
........................................................................................14
..............................................................................................15
................................................................................................................................ 17
...........................................................................................................................................................17
6 Clinical investigation planning ...........................................................................................................................................................17
........................................................................................................................................................................................................ 17
..............................................................................................................................................................................
...................................................................................................................................................................................
.....
............................................................................................................................
....................................................................................
............................................................................................................................................
.....................................................................................................................................................
............................................................................................................................................................ 20
................................................................................................................................................................................... 20
........................................................................................................................................................ 21
......................................................................................................................................................................................... 21
.................................................................................................................................................................................................... 21
...................................................................................................................................21
7 Clinical investigation conduct ..............................................................................................................................................................22
........................................................................................................................................................................................................ 22
....................................................................................................................................................... 22
..................................................................................................................................................22
.........................................................................................................................22
............................................................................................................. 22
7.4.2 Adverse events ................................................................................................................................................................ 23
......................................................................................................................................................23
..................................................23
...................................................................................... 24
7.5.1 Amendments .................................................................................................................................................................... 24
....................................................................................................................................... 24
© ISO 2020 – All rights reserved iii
Contents
Copyright International Organization for Standardization
Provided by IHS Markit under license with Standards Council of Canada
Not for Resale, 08/01/2020 07:24:26 MDT
No reproduction or networking permitted without license from IHS
--`,``,,`,``,`,,`,,,,,,,,,````-`-`,,`,,`,`,,`---
摘要:
展开>>
收起<<
Clinicalinvestigationofmedicaldevicesforhumansubjects—GoodclinicalpracticeInvestigationcliniquedesdispositifsmédicauxpoursujetshumains—Bonnepratiqueclinique©ISO2020INTERNATIONALSTANDARDISO14155Thirdedition2020-07ReferencenumberISO14155:2020(E)CopyrightInternationalOrganizationforStandardizationProvi...
声明:如果您的权利被侵害,请联系我们的进行举报。
相关推荐
-
浅析体外诊断试剂成品检验及留样检验的若干要求
2024-05-21 115 -
浅谈螺杆桩螺纹段长度对承载力的影响
2024-05-21 85 -
溶解细菌纤维素的方法VIP免费
2024-05-21 92 -
Box-Cox变换及其在STATA软件中的实现VIP免费
2024-07-10 110 -
IEC60601-1-2_...电放电抗扰度测试变化及对策VIP免费
2025-04-12 71 -
9.2025年版《中国药典》四部理化分析通用技术要求增修订概况
2025-04-12 56 -
8.2025年版《中国药典》(四部)通用技术要求和指导原则增修订概况
2025-04-12 92 -
7.2025年版《中国药典》三部通则0237国家生物标准物质研制解读
2025-04-12 103 -
6.2025年版《中国药典》三部关于异常毒性检查修订内容的解读
2025-04-12 81 -
医疗器械注册资料技术审评探讨VIP免费
2025-09-16 79
作者:多多猪
分类:法规规范
价格:50质量币
属性:90 页
大小:1.33MB
格式:PDF
时间:2025-09-17

